nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—type 2 diabetes mellitus	0.506	0.887	CbGaD
Maraviroc—CYP3A4—type 2 diabetes mellitus	0.0645	0.113	CbGaD
Maraviroc—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0344	0.152	CbGbCtD
Maraviroc—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0306	0.136	CbGbCtD
Maraviroc—CYP3A4—Glipizide—type 2 diabetes mellitus	0.028	0.124	CbGbCtD
Maraviroc—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0245	0.109	CbGbCtD
Maraviroc—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0221	0.0982	CbGbCtD
Maraviroc—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0168	0.0744	CbGbCtD
Maraviroc—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0161	0.0713	CbGbCtD
Maraviroc—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0161	0.0713	CbGbCtD
Maraviroc—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0152	0.0675	CbGbCtD
Maraviroc—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0113	0.0503	CbGbCtD
Maraviroc—CYP3A4—Losartan—type 2 diabetes mellitus	0.0104	0.046	CbGbCtD
Maraviroc—CCR5—Disease—SLC2A2—type 2 diabetes mellitus	0.000103	0.00166	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000102	0.00164	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTR—type 2 diabetes mellitus	0.000101	0.00163	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.0001	0.00162	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.0001	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	9.97e-05	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GHRL—type 2 diabetes mellitus	9.93e-05	0.0016	CbGpPWpGaD
Maraviroc—CCR5—Disease—NAMPT—type 2 diabetes mellitus	9.91e-05	0.0016	CbGpPWpGaD
Maraviroc—CCR5—Disease—GCK—type 2 diabetes mellitus	9.85e-05	0.00159	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	9.84e-05	0.00159	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CALCA—type 2 diabetes mellitus	9.8e-05	0.00158	CbGpPWpGaD
Maraviroc—CCR5—Disease—IAPP—type 2 diabetes mellitus	9.79e-05	0.00158	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL2—type 2 diabetes mellitus	9.78e-05	0.00158	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC9A1—type 2 diabetes mellitus	9.61e-05	0.00155	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	9.6e-05	0.00155	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TLE4—type 2 diabetes mellitus	9.34e-05	0.00151	CbGpPWpGaD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	9.25e-05	0.00149	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GCG—type 2 diabetes mellitus	9.08e-05	0.00146	CbGpPWpGaD
Maraviroc—CCR5—Disease—HMGA1—type 2 diabetes mellitus	9.01e-05	0.00145	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADRB3—type 2 diabetes mellitus	8.99e-05	0.00145	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	8.93e-05	0.00144	CbGpPWpGaD
Maraviroc—CCR5—Disease—PSMD6—type 2 diabetes mellitus	8.83e-05	0.00142	CbGpPWpGaD
Maraviroc—CCR5—Disease—SNAP25—type 2 diabetes mellitus	8.83e-05	0.00142	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CRHR1—type 2 diabetes mellitus	8.68e-05	0.0014	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	8.62e-05	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Disease—CYBA—type 2 diabetes mellitus	8.55e-05	0.00138	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AVP—type 2 diabetes mellitus	8.5e-05	0.00137	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	8.47e-05	0.00137	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	8.37e-05	0.00135	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	8.3e-05	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Disease—CALCA—type 2 diabetes mellitus	8.27e-05	0.00133	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	8.19e-05	0.00132	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	8.09e-05	0.0013	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	8.01e-05	0.00129	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC2A1—type 2 diabetes mellitus	7.99e-05	0.00129	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPRY2—type 2 diabetes mellitus	7.94e-05	0.00128	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	7.94e-05	0.00128	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS1—type 2 diabetes mellitus	7.87e-05	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GNB3—type 2 diabetes mellitus	7.82e-05	0.00126	CbGpPWpGaD
Maraviroc—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	7.81e-05	0.000548	CcSEcCtD
Maraviroc—Vomiting—Glipizide—type 2 diabetes mellitus	7.8e-05	0.000548	CcSEcCtD
Maraviroc—Syncope—Metformin—type 2 diabetes mellitus	7.79e-05	0.000547	CcSEcCtD
Maraviroc—CCR5—Disease—TCF7L2—type 2 diabetes mellitus	7.79e-05	0.00126	CbGpPWpGaD
Maraviroc—Oedema—Valsartan—type 2 diabetes mellitus	7.79e-05	0.000547	CcSEcCtD
Maraviroc—Dizziness—Pioglitazone—type 2 diabetes mellitus	7.77e-05	0.000546	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GLP1R—type 2 diabetes mellitus	7.74e-05	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RBP4—type 2 diabetes mellitus	7.74e-05	0.00125	CbGpPWpGaD
Maraviroc—Infection—Valsartan—type 2 diabetes mellitus	7.74e-05	0.000543	CcSEcCtD
Maraviroc—Rash—Glipizide—type 2 diabetes mellitus	7.73e-05	0.000543	CcSEcCtD
Maraviroc—Dermatitis—Glipizide—type 2 diabetes mellitus	7.73e-05	0.000542	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	7.72e-05	0.000542	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AVP—type 2 diabetes mellitus	7.72e-05	0.00124	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MMP3—type 2 diabetes mellitus	7.72e-05	0.00124	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	7.72e-05	0.000542	CcSEcCtD
Maraviroc—Erythema—Losartan—type 2 diabetes mellitus	7.72e-05	0.000542	CcSEcCtD
Maraviroc—Oedema—Orlistat—type 2 diabetes mellitus	7.69e-05	0.00054	CcSEcCtD
Maraviroc—Headache—Glipizide—type 2 diabetes mellitus	7.68e-05	0.000539	CcSEcCtD
Maraviroc—Tremor—Irbesartan—type 2 diabetes mellitus	7.68e-05	0.000539	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	7.68e-05	0.00124	CbGpPWpGaD
Maraviroc—Insomnia—Gliclazide—type 2 diabetes mellitus	7.67e-05	0.000538	CcSEcCtD
Maraviroc—Shock—Valsartan—type 2 diabetes mellitus	7.66e-05	0.000538	CcSEcCtD
Maraviroc—CCR5—Disease—SLC2A4—type 2 diabetes mellitus	7.66e-05	0.00124	CbGpPWpGaD
Maraviroc—Infection—Orlistat—type 2 diabetes mellitus	7.64e-05	0.000537	CcSEcCtD
Maraviroc—Loss of consciousness—Metformin—type 2 diabetes mellitus	7.64e-05	0.000536	CcSEcCtD
Maraviroc—Nervous system disorder—Valsartan—type 2 diabetes mellitus	7.64e-05	0.000536	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCKAR—type 2 diabetes mellitus	7.61e-05	0.00123	CbGpPWpGaD
Maraviroc—Paraesthesia—Gliclazide—type 2 diabetes mellitus	7.61e-05	0.000534	CcSEcCtD
Maraviroc—Flatulence—Losartan—type 2 diabetes mellitus	7.6e-05	0.000534	CcSEcCtD
Maraviroc—Anaemia—Irbesartan—type 2 diabetes mellitus	7.58e-05	0.000532	CcSEcCtD
Maraviroc—Dizziness—Glimepiride—type 2 diabetes mellitus	7.57e-05	0.000531	CcSEcCtD
Maraviroc—Skin disorder—Valsartan—type 2 diabetes mellitus	7.56e-05	0.000531	CcSEcCtD
Maraviroc—Nervous system disorder—Orlistat—type 2 diabetes mellitus	7.55e-05	0.00053	CcSEcCtD
Maraviroc—Dizziness—Sitagliptin—type 2 diabetes mellitus	7.54e-05	0.00053	CcSEcCtD
Maraviroc—Skin disorder—Orlistat—type 2 diabetes mellitus	7.47e-05	0.000525	CcSEcCtD
Maraviroc—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	7.47e-05	0.000524	CcSEcCtD
Maraviroc—Abdominal pain—Glyburide—type 2 diabetes mellitus	7.46e-05	0.000524	CcSEcCtD
Maraviroc—Anorexia—Valsartan—type 2 diabetes mellitus	7.42e-05	0.000521	CcSEcCtD
Maraviroc—Asthenia—Bromocriptine—type 2 diabetes mellitus	7.41e-05	0.00052	CcSEcCtD
Maraviroc—Myalgia—Metformin—type 2 diabetes mellitus	7.4e-05	0.000519	CcSEcCtD
Maraviroc—Headache—Pioglitazone—type 2 diabetes mellitus	7.36e-05	0.000517	CcSEcCtD
Maraviroc—Syncope—Irbesartan—type 2 diabetes mellitus	7.35e-05	0.000516	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	7.35e-05	0.000516	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EDN1—type 2 diabetes mellitus	7.34e-05	0.00118	CbGpPWpGaD
Maraviroc—Leukopenia—Irbesartan—type 2 diabetes mellitus	7.34e-05	0.000515	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	7.32e-05	0.000514	CcSEcCtD
Maraviroc—Discomfort—Metformin—type 2 diabetes mellitus	7.31e-05	0.000513	CcSEcCtD
Maraviroc—Fatigue—Gliclazide—type 2 diabetes mellitus	7.31e-05	0.000513	CcSEcCtD
Maraviroc—Nausea—Glipizide—type 2 diabetes mellitus	7.28e-05	0.000512	CcSEcCtD
Maraviroc—Vomiting—Glimepiride—type 2 diabetes mellitus	7.28e-05	0.000511	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	7.27e-05	0.00117	CbGpPWpGaD
Maraviroc—Vomiting—Sitagliptin—type 2 diabetes mellitus	7.25e-05	0.000509	CcSEcCtD
Maraviroc—Pain—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.000509	CcSEcCtD
Maraviroc—Constipation—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.000509	CcSEcCtD
Maraviroc—Tremor—Losartan—type 2 diabetes mellitus	7.23e-05	0.000508	CcSEcCtD
Maraviroc—Rash—Glimepiride—type 2 diabetes mellitus	7.22e-05	0.000507	CcSEcCtD
Maraviroc—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.21e-05	0.000506	CcSEcCtD
Maraviroc—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	7.21e-05	0.000506	CcSEcCtD
Maraviroc—Rash—Sitagliptin—type 2 diabetes mellitus	7.19e-05	0.000505	CcSEcCtD
Maraviroc—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.19e-05	0.000505	CcSEcCtD
Maraviroc—Erythema multiforme—Ramipril—type 2 diabetes mellitus	7.19e-05	0.000505	CcSEcCtD
Maraviroc—Headache—Glimepiride—type 2 diabetes mellitus	7.17e-05	0.000503	CcSEcCtD
Maraviroc—Cough—Irbesartan—type 2 diabetes mellitus	7.16e-05	0.000502	CcSEcCtD
Maraviroc—Headache—Sitagliptin—type 2 diabetes mellitus	7.15e-05	0.000502	CcSEcCtD
Maraviroc—Anaemia—Losartan—type 2 diabetes mellitus	7.13e-05	0.000501	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	7.09e-05	0.000498	CcSEcCtD
Maraviroc—Oedema—Metformin—type 2 diabetes mellitus	7.09e-05	0.000498	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	7.09e-05	0.00114	CbGpPWpGaD
Maraviroc—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7.06e-05	0.000496	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—C3—type 2 diabetes mellitus	7.06e-05	0.00114	CbGpPWpGaD
Maraviroc—Infection—Metformin—type 2 diabetes mellitus	7.04e-05	0.000495	CcSEcCtD
Maraviroc—Insomnia—Valsartan—type 2 diabetes mellitus	7.04e-05	0.000495	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.01e-05	0.000492	CcSEcCtD
Maraviroc—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.99e-05	0.000491	CcSEcCtD
Maraviroc—Myalgia—Irbesartan—type 2 diabetes mellitus	6.98e-05	0.00049	CcSEcCtD
Maraviroc—Shock—Metformin—type 2 diabetes mellitus	6.98e-05	0.00049	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	6.97e-05	0.00112	CbGpPWpGaD
Maraviroc—Insomnia—Orlistat—type 2 diabetes mellitus	6.96e-05	0.000489	CcSEcCtD
Maraviroc—Anxiety—Irbesartan—type 2 diabetes mellitus	6.96e-05	0.000488	CcSEcCtD
Maraviroc—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.95e-05	0.000488	CcSEcCtD
Maraviroc—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.95e-05	0.000488	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.93e-05	0.000487	CcSEcCtD
Maraviroc—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.93e-05	0.000487	CcSEcCtD
Maraviroc—Syncope—Losartan—type 2 diabetes mellitus	6.92e-05	0.000486	CcSEcCtD
Maraviroc—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.91e-05	0.000485	CcSEcCtD
Maraviroc—Leukopenia—Losartan—type 2 diabetes mellitus	6.91e-05	0.000485	CcSEcCtD
Maraviroc—Discomfort—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000484	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	6.9e-05	0.00111	CbGpPWpGaD
Maraviroc—Skin disorder—Metformin—type 2 diabetes mellitus	6.89e-05	0.000484	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IAPP—type 2 diabetes mellitus	6.85e-05	0.00111	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.85e-05	0.000481	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	6.85e-05	0.0011	CbGpPWpGaD
Maraviroc—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.83e-05	0.000479	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—INSR—type 2 diabetes mellitus	6.81e-05	0.0011	CbGpPWpGaD
Maraviroc—Nausea—Glimepiride—type 2 diabetes mellitus	6.8e-05	0.000477	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	6.8e-05	0.0011	CbGpPWpGaD
Maraviroc—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.78e-05	0.000476	CcSEcCtD
Maraviroc—Nausea—Sitagliptin—type 2 diabetes mellitus	6.78e-05	0.000476	CcSEcCtD
Maraviroc—Asthenia—Glyburide—type 2 diabetes mellitus	6.77e-05	0.000475	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	6.77e-05	0.00109	CbGpPWpGaD
Maraviroc—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.77e-05	0.000475	CcSEcCtD
Maraviroc—Anorexia—Metformin—type 2 diabetes mellitus	6.76e-05	0.000475	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	6.76e-05	0.00109	CbGpPWpGaD
Maraviroc—Cough—Losartan—type 2 diabetes mellitus	6.73e-05	0.000473	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	6.72e-05	0.00108	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.72e-05	0.000472	CcSEcCtD
Maraviroc—Alopecia—Ramipril—type 2 diabetes mellitus	6.72e-05	0.000472	CcSEcCtD
Maraviroc—Fatigue—Valsartan—type 2 diabetes mellitus	6.71e-05	0.000471	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AGT—type 2 diabetes mellitus	6.71e-05	0.00108	CbGpPWpGaD
Maraviroc—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.7e-05	0.00047	CcSEcCtD
Maraviroc—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.7e-05	0.00047	CcSEcCtD
Maraviroc—Oedema—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.00047	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TRPC6—type 2 diabetes mellitus	6.69e-05	0.00108	CbGpPWpGaD
Maraviroc—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.69e-05	0.00047	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	6.68e-05	0.00108	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	6.68e-05	0.00108	CbGpPWpGaD
Maraviroc—Pruritus—Glyburide—type 2 diabetes mellitus	6.68e-05	0.000469	CcSEcCtD
Maraviroc—CCR5—Disease—TGFBR2—type 2 diabetes mellitus	6.66e-05	0.00107	CbGpPWpGaD
Maraviroc—Mental disorder—Ramipril—type 2 diabetes mellitus	6.66e-05	0.000468	CcSEcCtD
Maraviroc—Constipation—Valsartan—type 2 diabetes mellitus	6.66e-05	0.000468	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AGTR2—type 2 diabetes mellitus	6.65e-05	0.00107	CbGpPWpGaD
Maraviroc—Infection—Irbesartan—type 2 diabetes mellitus	6.65e-05	0.000467	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.64e-05	0.000466	CcSEcCtD
Maraviroc—Fatigue—Orlistat—type 2 diabetes mellitus	6.63e-05	0.000466	CcSEcCtD
Maraviroc—Malnutrition—Ramipril—type 2 diabetes mellitus	6.62e-05	0.000465	CcSEcCtD
Maraviroc—Erythema—Ramipril—type 2 diabetes mellitus	6.62e-05	0.000465	CcSEcCtD
Maraviroc—Shock—Irbesartan—type 2 diabetes mellitus	6.58e-05	0.000462	CcSEcCtD
Maraviroc—Pain—Orlistat—type 2 diabetes mellitus	6.58e-05	0.000462	CcSEcCtD
Maraviroc—Myalgia—Losartan—type 2 diabetes mellitus	6.57e-05	0.000461	CcSEcCtD
Maraviroc—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.56e-05	0.000461	CcSEcCtD
Maraviroc—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.56e-05	0.000461	CcSEcCtD
Maraviroc—Anxiety—Losartan—type 2 diabetes mellitus	6.55e-05	0.00046	CcSEcCtD
Maraviroc—Rash—Bromocriptine—type 2 diabetes mellitus	6.51e-05	0.000457	CcSEcCtD
Maraviroc—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.5e-05	0.000457	CcSEcCtD
Maraviroc—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.000456	CcSEcCtD
Maraviroc—Discomfort—Losartan—type 2 diabetes mellitus	6.49e-05	0.000456	CcSEcCtD
Maraviroc—Headache—Bromocriptine—type 2 diabetes mellitus	6.47e-05	0.000454	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.46e-05	0.000454	CcSEcCtD
Maraviroc—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.46e-05	0.000453	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN2B—type 2 diabetes mellitus	6.45e-05	0.00104	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—C3—type 2 diabetes mellitus	6.41e-05	0.00103	CbGpPWpGaD
Maraviroc—Anorexia—Irbesartan—type 2 diabetes mellitus	6.38e-05	0.000448	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EDNRB—type 2 diabetes mellitus	6.37e-05	0.00103	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.37e-05	0.000447	CcSEcCtD
Maraviroc—Paraesthesia—Metformin—type 2 diabetes mellitus	6.37e-05	0.000447	CcSEcCtD
Maraviroc—Oedema—Losartan—type 2 diabetes mellitus	6.3e-05	0.000442	CcSEcCtD
Maraviroc—CCR5—Disease—APOB—type 2 diabetes mellitus	6.29e-05	0.00102	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.29e-05	0.000442	CcSEcCtD
Maraviroc—Infection—Losartan—type 2 diabetes mellitus	6.26e-05	0.000439	CcSEcCtD
Maraviroc—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.24e-05	0.000438	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	6.2e-05	0.001	CbGpPWpGaD
Maraviroc—Tremor—Ramipril—type 2 diabetes mellitus	6.2e-05	0.000435	CcSEcCtD
Maraviroc—Shock—Losartan—type 2 diabetes mellitus	6.2e-05	0.000435	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PSMD6—type 2 diabetes mellitus	6.19e-05	0.000998	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HTR2C—type 2 diabetes mellitus	6.19e-05	0.000998	CbGpPWpGaD
Maraviroc—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.18e-05	0.000434	CcSEcCtD
Maraviroc—Decreased appetite—Metformin—type 2 diabetes mellitus	6.16e-05	0.000433	CcSEcCtD
Maraviroc—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.16e-05	0.000432	CcSEcCtD
Maraviroc—Nausea—Bromocriptine—type 2 diabetes mellitus	6.13e-05	0.000431	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.12e-05	0.00043	CcSEcCtD
Maraviroc—Fatigue—Metformin—type 2 diabetes mellitus	6.11e-05	0.000429	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.1e-05	0.000428	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AGT—type 2 diabetes mellitus	6.09e-05	0.000983	CbGpPWpGaD
Maraviroc—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.08e-05	0.000427	CcSEcCtD
Maraviroc—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.08e-05	0.000427	CcSEcCtD
Maraviroc—Asthenia—Gliclazide—type 2 diabetes mellitus	6.08e-05	0.000427	CcSEcCtD
Maraviroc—Constipation—Metformin—type 2 diabetes mellitus	6.06e-05	0.000426	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EDNRA—type 2 diabetes mellitus	6.02e-05	0.00097	CbGpPWpGaD
Maraviroc—CCR5—Disease—LPL—type 2 diabetes mellitus	6.01e-05	0.000969	CbGpPWpGaD
Maraviroc—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.01e-05	0.000422	CcSEcCtD
Maraviroc—Anorexia—Losartan—type 2 diabetes mellitus	6e-05	0.000421	CcSEcCtD
Maraviroc—Vomiting—Glyburide—type 2 diabetes mellitus	6e-05	0.000421	CcSEcCtD
Maraviroc—Pruritus—Gliclazide—type 2 diabetes mellitus	6e-05	0.000421	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CALM1—type 2 diabetes mellitus	5.99e-05	0.000966	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CYBA—type 2 diabetes mellitus	5.99e-05	0.000966	CbGpPWpGaD
Maraviroc—Rash—Glyburide—type 2 diabetes mellitus	5.95e-05	0.000418	CcSEcCtD
Maraviroc—Dermatitis—Glyburide—type 2 diabetes mellitus	5.95e-05	0.000417	CcSEcCtD
Maraviroc—Syncope—Ramipril—type 2 diabetes mellitus	5.93e-05	0.000417	CcSEcCtD
Maraviroc—Leukopenia—Ramipril—type 2 diabetes mellitus	5.92e-05	0.000416	CcSEcCtD
Maraviroc—Headache—Glyburide—type 2 diabetes mellitus	5.91e-05	0.000415	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	5.89e-05	0.00095	CbGpPWpGaD
Maraviroc—CCR5—Disease—ADCY5—type 2 diabetes mellitus	5.88e-05	0.000949	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLAT—type 2 diabetes mellitus	5.86e-05	0.000946	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.86e-05	0.000946	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	5.86e-05	0.000945	CbGpPWpGaD
Maraviroc—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.82e-05	0.000408	CcSEcCtD
Maraviroc—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.82e-05	0.000408	CcSEcCtD
Maraviroc—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.8e-05	0.000407	CcSEcCtD
Maraviroc—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.8e-05	0.000407	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CALCA—type 2 diabetes mellitus	5.79e-05	0.000934	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.78e-05	0.000406	CcSEcCtD
Maraviroc—Cough—Ramipril—type 2 diabetes mellitus	5.77e-05	0.000405	CcSEcCtD
Maraviroc—Fatigue—Irbesartan—type 2 diabetes mellitus	5.77e-05	0.000405	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.74e-05	0.000403	CcSEcCtD
Maraviroc—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.74e-05	0.000403	CcSEcCtD
Maraviroc—Convulsion—Ramipril—type 2 diabetes mellitus	5.73e-05	0.000403	CcSEcCtD
Maraviroc—Pain—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000402	CcSEcCtD
Maraviroc—Constipation—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000402	CcSEcCtD
Maraviroc—Insomnia—Losartan—type 2 diabetes mellitus	5.7e-05	0.0004	CcSEcCtD
Maraviroc—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.67e-05	0.000398	CcSEcCtD
Maraviroc—Paraesthesia—Losartan—type 2 diabetes mellitus	5.66e-05	0.000397	CcSEcCtD
Maraviroc—CCR5—Disease—PPP2CA—type 2 diabetes mellitus	5.64e-05	0.000909	CbGpPWpGaD
Maraviroc—Myalgia—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000396	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	5.63e-05	0.000908	CbGpPWpGaD
Maraviroc—Anxiety—Ramipril—type 2 diabetes mellitus	5.61e-05	0.000394	CcSEcCtD
Maraviroc—Nausea—Glyburide—type 2 diabetes mellitus	5.61e-05	0.000394	CcSEcCtD
Maraviroc—Abdominal pain—Metformin—type 2 diabetes mellitus	5.61e-05	0.000394	CcSEcCtD
Maraviroc—Dizziness—Gliclazide—type 2 diabetes mellitus	5.6e-05	0.000394	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000393	CcSEcCtD
Maraviroc—Asthenia—Valsartan—type 2 diabetes mellitus	5.59e-05	0.000392	CcSEcCtD
Maraviroc—Discomfort—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000391	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	5.55e-05	0.000895	CbGpPWpGaD
Maraviroc—Asthenia—Orlistat—type 2 diabetes mellitus	5.52e-05	0.000388	CcSEcCtD
Maraviroc—Pruritus—Valsartan—type 2 diabetes mellitus	5.51e-05	0.000387	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	5.49e-05	0.000885	CbGpPWpGaD
Maraviroc—Decreased appetite—Losartan—type 2 diabetes mellitus	5.47e-05	0.000384	CcSEcCtD
Maraviroc—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.47e-05	0.000384	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.45e-05	0.00088	CbGpPWpGaD
Maraviroc—Pruritus—Orlistat—type 2 diabetes mellitus	5.44e-05	0.000382	CcSEcCtD
Maraviroc—Fatigue—Losartan—type 2 diabetes mellitus	5.43e-05	0.000381	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	5.43e-05	0.000876	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTHFR—type 2 diabetes mellitus	5.41e-05	0.000873	CbGpPWpGaD
Maraviroc—Oedema—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000379	CcSEcCtD
Maraviroc—Vomiting—Gliclazide—type 2 diabetes mellitus	5.39e-05	0.000378	CcSEcCtD
Maraviroc—Constipation—Losartan—type 2 diabetes mellitus	5.39e-05	0.000378	CcSEcCtD
Maraviroc—Pain—Losartan—type 2 diabetes mellitus	5.39e-05	0.000378	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GCG—type 2 diabetes mellitus	5.36e-05	0.000865	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.36e-05	0.000865	CbGpPWpGaD
Maraviroc—Rash—Gliclazide—type 2 diabetes mellitus	5.34e-05	0.000375	CcSEcCtD
Maraviroc—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.34e-05	0.000375	CcSEcCtD
Maraviroc—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.33e-05	0.000374	CcSEcCtD
Maraviroc—Shock—Ramipril—type 2 diabetes mellitus	5.31e-05	0.000373	CcSEcCtD
Maraviroc—Headache—Gliclazide—type 2 diabetes mellitus	5.31e-05	0.000373	CcSEcCtD
Maraviroc—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.3e-05	0.000372	CcSEcCtD
Maraviroc—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.29e-05	0.000371	CcSEcCtD
Maraviroc—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.29e-05	0.000371	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.28e-05	0.000851	CbGpPWpGaD
Maraviroc—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.26e-05	0.00037	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.26e-05	0.000848	CbGpPWpGaD
Maraviroc—Skin disorder—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000368	CcSEcCtD
Maraviroc—CCR5—Disease—HIF1A—type 2 diabetes mellitus	5.16e-05	0.000832	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.15e-05	0.000362	CcSEcCtD
Maraviroc—Dizziness—Valsartan—type 2 diabetes mellitus	5.15e-05	0.000362	CcSEcCtD
Maraviroc—Anorexia—Ramipril—type 2 diabetes mellitus	5.15e-05	0.000361	CcSEcCtD
Maraviroc—CCR5—Disease—IRS2—type 2 diabetes mellitus	5.15e-05	0.00083	CbGpPWpGaD
Maraviroc—Dizziness—Orlistat—type 2 diabetes mellitus	5.09e-05	0.000357	CcSEcCtD
Maraviroc—Asthenia—Metformin—type 2 diabetes mellitus	5.09e-05	0.000357	CcSEcCtD
Maraviroc—CCR5—Disease—CALM1—type 2 diabetes mellitus	5.06e-05	0.000815	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOE—type 2 diabetes mellitus	5.04e-05	0.000812	CbGpPWpGaD
Maraviroc—Nausea—Gliclazide—type 2 diabetes mellitus	5.03e-05	0.000353	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.02e-05	0.000809	CbGpPWpGaD
Maraviroc—Pruritus—Metformin—type 2 diabetes mellitus	5.02e-05	0.000352	CcSEcCtD
Maraviroc—CCR5—Disease—APOA1—type 2 diabetes mellitus	4.98e-05	0.000803	CbGpPWpGaD
Maraviroc—Body temperature increased—Losartan—type 2 diabetes mellitus	4.98e-05	0.00035	CcSEcCtD
Maraviroc—Abdominal pain—Losartan—type 2 diabetes mellitus	4.98e-05	0.00035	CcSEcCtD
Maraviroc—Vomiting—Valsartan—type 2 diabetes mellitus	4.95e-05	0.000348	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT2—type 2 diabetes mellitus	4.93e-05	0.000795	CbGpPWpGaD
Maraviroc—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000346	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	4.93e-05	0.000795	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.92e-05	0.000345	CcSEcCtD
Maraviroc—Rash—Valsartan—type 2 diabetes mellitus	4.91e-05	0.000345	CcSEcCtD
Maraviroc—Dermatitis—Valsartan—type 2 diabetes mellitus	4.91e-05	0.000344	CcSEcCtD
Maraviroc—Vomiting—Orlistat—type 2 diabetes mellitus	4.89e-05	0.000344	CcSEcCtD
Maraviroc—Insomnia—Ramipril—type 2 diabetes mellitus	4.88e-05	0.000343	CcSEcCtD
Maraviroc—Headache—Valsartan—type 2 diabetes mellitus	4.88e-05	0.000343	CcSEcCtD
Maraviroc—Diarrhoea—Metformin—type 2 diabetes mellitus	4.85e-05	0.000341	CcSEcCtD
Maraviroc—Rash—Orlistat—type 2 diabetes mellitus	4.85e-05	0.000341	CcSEcCtD
Maraviroc—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.85e-05	0.00034	CcSEcCtD
Maraviroc—Dermatitis—Orlistat—type 2 diabetes mellitus	4.85e-05	0.00034	CcSEcCtD
Maraviroc—Headache—Orlistat—type 2 diabetes mellitus	4.82e-05	0.000338	CcSEcCtD
Maraviroc—Asthenia—Irbesartan—type 2 diabetes mellitus	4.8e-05	0.000337	CcSEcCtD
Maraviroc—Pruritus—Irbesartan—type 2 diabetes mellitus	4.73e-05	0.000332	CcSEcCtD
Maraviroc—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.69e-05	0.00033	CcSEcCtD
Maraviroc—CCR5—Disease—NOS2—type 2 diabetes mellitus	4.69e-05	0.000757	CbGpPWpGaD
Maraviroc—Dizziness—Metformin—type 2 diabetes mellitus	4.69e-05	0.000329	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.67e-05	0.000752	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000327	CcSEcCtD
Maraviroc—Fatigue—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000327	CcSEcCtD
Maraviroc—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.64e-05	0.000326	CcSEcCtD
Maraviroc—Nausea—Valsartan—type 2 diabetes mellitus	4.63e-05	0.000325	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.62e-05	0.000745	CbGpPWpGaD
Maraviroc—Constipation—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000324	CcSEcCtD
Maraviroc—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.58e-05	0.000321	CcSEcCtD
Maraviroc—Nausea—Orlistat—type 2 diabetes mellitus	4.57e-05	0.000321	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AVP—type 2 diabetes mellitus	4.56e-05	0.000735	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.56e-05	0.000735	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.54e-05	0.000732	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.52e-05	0.000729	CbGpPWpGaD
Maraviroc—Asthenia—Losartan—type 2 diabetes mellitus	4.52e-05	0.000317	CcSEcCtD
Maraviroc—Vomiting—Metformin—type 2 diabetes mellitus	4.51e-05	0.000317	CcSEcCtD
Maraviroc—CCR5—Disease—IRS1—type 2 diabetes mellitus	4.49e-05	0.000725	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.47e-05	0.000721	CbGpPWpGaD
Maraviroc—Rash—Metformin—type 2 diabetes mellitus	4.47e-05	0.000314	CcSEcCtD
Maraviroc—Dermatitis—Metformin—type 2 diabetes mellitus	4.47e-05	0.000314	CcSEcCtD
Maraviroc—Pruritus—Losartan—type 2 diabetes mellitus	4.46e-05	0.000313	CcSEcCtD
Maraviroc—Headache—Metformin—type 2 diabetes mellitus	4.44e-05	0.000312	CcSEcCtD
Maraviroc—Dizziness—Irbesartan—type 2 diabetes mellitus	4.43e-05	0.000311	CcSEcCtD
Maraviroc—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.42e-05	0.00031	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOB—type 2 diabetes mellitus	4.41e-05	0.000711	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.39e-05	0.000708	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.34e-05	0.0007	CbGpPWpGaD
Maraviroc—Diarrhoea—Losartan—type 2 diabetes mellitus	4.31e-05	0.000303	CcSEcCtD
Maraviroc—CCR5—Disease—INS—type 2 diabetes mellitus	4.3e-05	0.000694	CbGpPWpGaD
Maraviroc—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.27e-05	0.0003	CcSEcCtD
Maraviroc—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.27e-05	0.0003	CcSEcCtD
Maraviroc—Vomiting—Irbesartan—type 2 diabetes mellitus	4.25e-05	0.000299	CcSEcCtD
Maraviroc—Rash—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000296	CcSEcCtD
Maraviroc—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000296	CcSEcCtD
Maraviroc—Nausea—Metformin—type 2 diabetes mellitus	4.21e-05	0.000296	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—LPL—type 2 diabetes mellitus	4.21e-05	0.000679	CbGpPWpGaD
Maraviroc—Headache—Irbesartan—type 2 diabetes mellitus	4.19e-05	0.000294	CcSEcCtD
Maraviroc—Dizziness—Losartan—type 2 diabetes mellitus	4.16e-05	0.000292	CcSEcCtD
Maraviroc—CCR5—Disease—AKT2—type 2 diabetes mellitus	4.16e-05	0.000671	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.12e-05	0.000664	CbGpPWpGaD
Maraviroc—Vomiting—Losartan—type 2 diabetes mellitus	4e-05	0.000281	CcSEcCtD
Maraviroc—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000279	CcSEcCtD
Maraviroc—Nausea—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.000279	CcSEcCtD
Maraviroc—Rash—Losartan—type 2 diabetes mellitus	3.97e-05	0.000279	CcSEcCtD
Maraviroc—Dermatitis—Losartan—type 2 diabetes mellitus	3.97e-05	0.000279	CcSEcCtD
Maraviroc—CCR5—Disease—SERPINE1—type 2 diabetes mellitus	3.95e-05	0.000637	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.95e-05	0.000637	CbGpPWpGaD
Maraviroc—Headache—Losartan—type 2 diabetes mellitus	3.95e-05	0.000277	CcSEcCtD
Maraviroc—Asthenia—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000272	CcSEcCtD
Maraviroc—Pruritus—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000268	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—C3—type 2 diabetes mellitus	3.79e-05	0.000611	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS3—type 2 diabetes mellitus	3.77e-05	0.000609	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3R1—type 2 diabetes mellitus	3.77e-05	0.000609	CbGpPWpGaD
Maraviroc—Nausea—Losartan—type 2 diabetes mellitus	3.74e-05	0.000263	CcSEcCtD
Maraviroc—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.69e-05	0.000259	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	3.69e-05	0.000595	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.61e-05	0.000583	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.6e-05	0.000581	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGT—type 2 diabetes mellitus	3.6e-05	0.000581	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	3.57e-05	0.000576	CbGpPWpGaD
Maraviroc—Dizziness—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000251	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.54e-05	0.000571	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOE—type 2 diabetes mellitus	3.53e-05	0.000569	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LEP—type 2 diabetes mellitus	3.53e-05	0.000569	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	3.52e-05	0.000568	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.49e-05	0.000562	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—type 2 diabetes mellitus	3.45e-05	0.000557	CbGpPWpGaD
Maraviroc—Vomiting—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000241	CcSEcCtD
Maraviroc—Rash—Ramipril—type 2 diabetes mellitus	3.4e-05	0.000239	CcSEcCtD
Maraviroc—Dermatitis—Ramipril—type 2 diabetes mellitus	3.4e-05	0.000239	CcSEcCtD
Maraviroc—Headache—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000238	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.33e-05	0.000537	CbGpPWpGaD
Maraviroc—Nausea—Ramipril—type 2 diabetes mellitus	3.21e-05	0.000225	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.15e-05	0.000508	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—INS—type 2 diabetes mellitus	3.01e-05	0.000486	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.96e-05	0.000478	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	2.95e-05	0.000476	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	2.92e-05	0.00047	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.91e-05	0.00047	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.91e-05	0.00047	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	2.91e-05	0.000469	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.9e-05	0.000468	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	2.88e-05	0.000464	CbGpPWpGaD
Maraviroc—CCR5—Disease—SRC—type 2 diabetes mellitus	2.79e-05	0.00045	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.77e-05	0.000446	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.64e-05	0.000426	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.64e-05	0.000426	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—type 2 diabetes mellitus	2.5e-05	0.000402	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RELA—type 2 diabetes mellitus	2.49e-05	0.000401	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—type 2 diabetes mellitus	2.45e-05	0.000395	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.26e-05	0.000365	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.24e-05	0.000362	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	2.23e-05	0.00036	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.23e-05	0.000359	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	2.2e-05	0.000355	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.12e-05	0.000342	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.1e-05	0.000338	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.06e-05	0.000332	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SRC—type 2 diabetes mellitus	1.95e-05	0.000315	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.9e-05	0.000307	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—type 2 diabetes mellitus	1.88e-05	0.000303	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.75e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—type 2 diabetes mellitus	1.73e-05	0.00028	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.71e-05	0.000276	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	1.7e-05	0.000275	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	1.49e-05	0.00024	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	1.49e-05	0.00024	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.41e-05	0.000228	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.41e-05	0.000228	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.35e-05	0.000217	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.32e-05	0.000212	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.24e-05	0.000201	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.24e-05	0.000201	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.21e-05	0.000196	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.2e-05	0.000194	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.2e-05	0.000194	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.2e-05	0.000194	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.2e-05	0.000194	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.2e-05	0.000194	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.16e-05	0.000188	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.1e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.1e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.07e-05	0.000173	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.02e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.02e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.02e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	9.79e-06	0.000158	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	9.79e-06	0.000158	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	9.42e-06	0.000152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	9.42e-06	0.000152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	9.26e-06	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	9.1e-06	0.000147	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	9.1e-06	0.000147	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	9.1e-06	0.000147	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	8.56e-06	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	8.01e-06	0.000129	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	7.74e-06	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	7.74e-06	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	7.74e-06	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	7.74e-06	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	7.42e-06	0.00012	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.9e-06	0.000111	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.44e-06	0.000104	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.31e-06	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.31e-06	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.19e-06	9.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.15e-06	9.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.15e-06	9.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.15e-06	9.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.11e-06	9.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6e-06	9.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.93e-06	9.56e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.51e-06	8.89e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.51e-06	8.89e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.51e-06	8.89e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.41e-06	8.73e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.36e-06	8.65e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.25e-06	8.46e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.04e-06	8.13e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.99e-06	8.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.99e-06	8.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.78e-06	7.71e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.78e-06	7.71e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.12e-06	6.64e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.12e-06	6.64e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.1e-06	6.61e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.05e-06	6.53e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.93e-06	6.34e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.82e-06	6.16e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.75e-06	6.05e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.67e-06	5.92e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.66e-06	5.9e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.56e-06	5.75e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.52e-06	5.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.38e-06	5.45e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.31e-06	5.34e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.21e-06	5.18e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.16e-06	5.09e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.14e-06	5.07e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.11e-06	5.01e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.74e-06	4.42e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.69e-06	4.33e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.46e-06	3.97e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.36e-06	3.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.36e-06	3.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.15e-06	3.47e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.08e-06	1.75e-05	CbGpPWpGaD
